These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16199914)

  • 1. [Calcium antagonists and insulin resistance].
    Higashi Y; Yoshizumi M
    Clin Calcium; 2005 Oct; 15(10):1675-80. PubMed ID: 16199914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Calcium antagonists and endothelial function].
    Yasuda O; Kawamoto H; Yokoi T; Rakugi H; Ogihara T
    Clin Calcium; 2005 Oct; 15(10):1663-8. PubMed ID: 16199912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of calcium channel blockers in atherosclerosis and cardiovascular event and oxidative vascular damage].
    Fujino T; Sumitomo K; Hasebe N; Kikuchi K
    Clin Calcium; 2004 Jan; 14(1):119-27. PubMed ID: 15576967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases.
    Cersosimo E; DeFronzo RA
    Diabetes Metab Res Rev; 2006; 22(6):423-36. PubMed ID: 16506274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.
    Sarafidis PA; Bakris GL
    QJM; 2006 Jul; 99(7):431-6. PubMed ID: 16766516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome.
    Sowers JR
    Nephrol Dial Transplant; 1995 Oct; 10 Suppl 9():52-5. PubMed ID: 8643209
    [No Abstract]   [Full Text] [Related]  

  • 9. Calcium channel blockers, endothelial dysfunction, and combination therapy.
    Schulman IH; Zachariah M; Raij L
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):40-5. PubMed ID: 16640172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ; Sposito AC
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic syndrome: metabolic changes with vascular consequences.
    Wassink AM; Olijhoek JK; Visseren FL
    Eur J Clin Invest; 2007 Jan; 37(1):8-17. PubMed ID: 17181562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
    Ribeiro AB
    Curr Med Res Opin; 2006 Jan; 22(1):1-16. PubMed ID: 16393425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolic syndrome in hypertension: European society of hypertension position statement.
    Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
    J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance and endothelial cell dysfunction: studies in mammalian models.
    Kearney MT; Duncan ER; Kahn M; Wheatcroft SB
    Exp Physiol; 2008 Jan; 93(1):158-63. PubMed ID: 17933859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive blood pressure control and stroke prevention: role of calcium channel blockers.
    Papadopoulos DP; Papademetriou V
    J Hypertens; 2008 May; 26(5):844-52. PubMed ID: 18398322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
    Perkins JM; Davis SN
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):147-52. PubMed ID: 18316950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Heart rate: a cardiovascular risk factor that can no longer be ignored].
    Palatini P
    G Ital Cardiol (Rome); 2006 Feb; 7(2):119-28. PubMed ID: 16532723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.